31-08-2026 21:21 via medpagetoday.com

First-in-Class Drug Wins FDA Approval for Polycythemia Vera

(MedPage Today) -- The FDA approved first-in-class rusfertide (Mimrylo) for treating erythrocytosis in adults with polycythemia vera (PV), a rare and slow-growing hematologic malignancy.
Rusfertide mimics hepcidin, the natural hormone involved...
Read more »